cytarabine + omacetaxine mepesuccinate + decitabine
Phase 2TerminatedDevelopment Stage
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Jul 1, 2014 → Dec 1, 2015
About cytarabine + omacetaxine mepesuccinate + decitabine
cytarabine + omacetaxine mepesuccinate + decitabine is a phase 2 stage product being developed by Teva Pharmaceutical Industries for Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT02029417. Target conditions include Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0).
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02029417 | Phase 2 | Terminated |
Competing Products
20 competing products in Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome